Agilent Technologies

Agilent Technologies, Inc., commonly known as Agilent, is a global American company headquartered in Santa Clara, California, founded in 1999 as a spin-off from Hewlett-Packard. It is a publicly traded company on the New York Stock Exchange under the ticker symbol "A". As of fiscal year 2025, Agilent reported revenues of $6.95 billion and employed approximately 18,000 people worldwide. Its market capitalization as of June 2026 was approximately $38.8 billion.

Agilent specializes in providing instruments, software, services, and consumables for laboratories across life sciences, diagnostics, and applied chemical markets. Its major product lines and services include gas and liquid chromatography, mass spectrometry, spectroscopy, cell analysis, genomics, and various laboratory management software and services. The company supports diverse applications, from drug discovery and cancer research to food safety and environmental testing.

In terms of patent litigation, Agilent Technologies appears to be an operating company actively defending and asserting its intellectual property. The provided data shows one tracked case where Agilent Technologies is the plaintiff. This aligns with an operating company posture that seeks to protect its innovations.

The notable tracked case, Agilent Technologies v. Synthego Corp., reached the U.S. Supreme Court, where the Court declined to hear Agilent's appeal as of April 2026. This case centered on the invalidation of two of Agilent's CRISPR gene-editing patents (U.S. Patent Nos. 10,337,001 and 10,900,034) by the Patent Trial and Appeal Board (PTAB), a decision affirmed by the Federal Circuit. Synthego Corp., a direct commercial competitor, challenged the patents using an abandoned patent application with prophetic examples as prior art. The Supreme Court's decision not to intervene finalized the invalidation of these foundational biotech patents covering chemically modified guide RNAs.